These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 33052557)

  • 1. The novel low molecular weight MYC antagonist MYCMI-6 inhibits proliferation and induces apoptosis in breast cancer cells.
    AlSultan D; Kavanagh E; O'Grady S; Eustace AJ; Castell A; Larsson LG; Crown J; Madden SF; Duffy MJ
    Invest New Drugs; 2021 Apr; 39(2):587-594. PubMed ID: 33052557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MYCMI-7: A Small MYC-Binding Compound that Inhibits MYC: MAX Interaction and Tumor Growth in a MYC-Dependent Manner.
    Castell A; Yan Q; Fawkner K; Bazzar W; Zhang F; Wickström M; Alzrigat M; Franco M; Krona C; Cameron DP; Dyberg C; Olsen TK; Verschut V; Schmidt L; Lim SY; Mahmoud L; Hydbring P; Lehmann S; Baranello L; Nelander S; Johnsen JI; Larsson LG
    Cancer Res Commun; 2022 Mar; 2(3):182-201. PubMed ID: 36874405
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A selective high affinity MYC-binding compound inhibits MYC:MAX interaction and MYC-dependent tumor cell proliferation.
    Castell A; Yan Q; Fawkner K; Hydbring P; Zhang F; Verschut V; Franco M; Zakaria SM; Bazzar W; Goodwin J; Zinzalla G; Larsson LG
    Sci Rep; 2018 Jul; 8(1):10064. PubMed ID: 29968736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of Jun loss promotes resistance to histone deacetylase inhibitor entinostat through Myc signaling in luminal breast cancer.
    Tanioka M; Mott KR; Hollern DP; Fan C; Darr DB; Perou CM
    Genome Med; 2018 Nov; 10(1):86. PubMed ID: 30497520
    [TBL] [Abstract][Full Text] [Related]  

  • 5. C-myc gene expression alone is sufficient to confer resistance to antiestrogen in human breast cancer cells.
    Venditti M; Iwasiow B; Orr FW; Shiu RP
    Int J Cancer; 2002 May; 99(1):35-42. PubMed ID: 11948489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting cyclin-dependent kinase 1 (CDK1) but not CDK4/6 or CDK2 is selectively lethal to MYC-dependent human breast cancer cells.
    Kang J; Sergio CM; Sutherland RL; Musgrove EA
    BMC Cancer; 2014 Jan; 14():32. PubMed ID: 24444383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic activity of letrozole and sorafenib on breast cancer cells.
    Bonelli MA; Fumarola C; Alfieri RR; La Monica S; Cavazzoni A; Galetti M; Gatti R; Belletti S; Harris AL; Fox SB; Evans DB; Dowsett M; Martin LA; Bottini A; Generali D; Petronini PG
    Breast Cancer Res Treat; 2010 Nov; 124(1):79-88. PubMed ID: 20054642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amplification of fibroblast growth factor receptor-1 in breast cancer and the effects of brivanib alaninate.
    Shiang CY; Qi Y; Wang B; Lazar V; Wang J; Fraser Symmans W; Hortobagyi GN; Andre F; Pusztai L
    Breast Cancer Res Treat; 2010 Oct; 123(3):747-55. PubMed ID: 20024612
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual HDAC and PI3K Inhibitor CUDC-907 Downregulates MYC and Suppresses Growth of MYC-dependent Cancers.
    Sun K; Atoyan R; Borek MA; Dellarocca S; Samson ME; Ma AW; Xu GX; Patterson T; Tuck DP; Viner JL; Fattaey A; Wang J
    Mol Cancer Ther; 2017 Feb; 16(2):285-299. PubMed ID: 27980108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. β-catenin regulates c-Myc and CDKN1A expression in breast cancer cells.
    Xu J; Chen Y; Huo D; Khramtsov A; Khramtsova G; Zhang C; Goss KH; Olopade OI
    Mol Carcinog; 2016 May; 55(5):431-9. PubMed ID: 25663530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Barasertib (AZD1152), a Small Molecule Aurora B Inhibitor, Inhibits the Growth of SCLC Cell Lines In Vitro and In Vivo.
    Helfrich BA; Kim J; Gao D; Chan DC; Zhang Z; Tan AC; Bunn PA
    Mol Cancer Ther; 2016 Oct; 15(10):2314-2322. PubMed ID: 27496133
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MYC as a therapeutic target for the treatment of triple-negative breast cancer: preclinical investigations with the novel MYC inhibitor, MYCi975.
    Tang M; O'Grady S; Crown J; Duffy MJ
    Breast Cancer Res Treat; 2022 Sep; 195(2):105-115. PubMed ID: 35908121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutant p53 as a therapeutic target for the treatment of triple-negative breast cancer: Preclinical investigation with the anti-p53 drug, PK11007.
    Synnott NC; Bauer MR; Madden S; Murray A; Klinger R; O'Donovan N; O'Connor D; Gallagher WM; Crown J; Fersht AR; Duffy MJ
    Cancer Lett; 2018 Feb; 414():99-106. PubMed ID: 29069577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ailanthone inhibits cell growth and migration of cisplatin resistant bladder cancer cells through down-regulation of Nrf2, YAP, and c-Myc expression.
    Daga M; Pizzimenti S; Dianzani C; Cucci MA; Cavalli R; Grattarola M; Ferrara B; Scariot V; Trotta F; Barrera G
    Phytomedicine; 2019 Mar; 56():156-164. PubMed ID: 30668336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro.
    Finn RS; Dering J; Conklin D; Kalous O; Cohen DJ; Desai AJ; Ginther C; Atefi M; Chen I; Fowst C; Los G; Slamon DJ
    Breast Cancer Res; 2009; 11(5):R77. PubMed ID: 19874578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of cell proliferation, induction of apoptosis, reactivation of DLC1, and modulation of other gene expression by dietary flavone in breast cancer cell lines.
    Ullmannova V; Popescu NC
    Cancer Detect Prev; 2007; 31(2):110-8. PubMed ID: 17418982
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ADA3 regulates normal and tumor mammary epithelial cell proliferation through c-MYC.
    Griffin NI; Sharma G; Zhao X; Mirza S; Srivastava S; Dave BJ; Aleskandarany M; Rakha E; Mohibi S; Band H; Band V
    Breast Cancer Res; 2016 Nov; 18(1):113. PubMed ID: 27852327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The dicyano compound induces autophagic or apoptotic cell death via Twist/c-Myc axis depending on metastatic characteristics of breast cancer cells.
    Alvur O; Kucuksayan H; Baygu Y; Kabay N; Gok Y; Akca H
    Mol Biol Rep; 2022 Jan; 49(1):39-50. PubMed ID: 34775571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MEDI3039, a novel highly potent tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 2 agonist, causes regression of orthotopic tumors and inhibits outgrowth of metastatic triple-negative breast cancer.
    Greer YE; Gilbert SF; Gril B; Narwal R; Peacock Brooks DL; Tice DA; Steeg PS; Lipkowitz S
    Breast Cancer Res; 2019 Feb; 21(1):27. PubMed ID: 30777098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. c-myc regulates the sensitivity of breast cancer cells to palbociclib via c-myc/miR-29b-3p/CDK6 axis.
    Ji W; Zhang W; Wang X; Shi Y; Yang F; Xie H; Zhou W; Wang S; Guan X
    Cell Death Dis; 2020 Sep; 11(9):760. PubMed ID: 32934206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.